The Expanding Role of Anti-IL-12 and/or Anti-IL-23 Antibodies in the Treatment of Inflammatory Bowel Disease. Article Swipe
The interleukin (IL)-12/IL-23 pathway is one of many proposed mechanistic pathways of intestinal inflammation. Earlier studies introduced IL-12 as a major cytokine in the pathogenesis of inflammatory bowel disease. However, the discovery of IL-23 drew attention toward this new cytokine. Overwhelming data indicated that antibodies against IL-12p40 rendered their anti-inflammatory effect primarily via inhibition of IL-23. This is because IL-12 and IL-23 have the subunit p40 in common. These cytokines have become an attractive target of treatment in patients with inflammatory bowel disease. Targeting IL-12 selectively was not found to be an efficacious treatment. Coblockade of IL-12 and IL-23 via targeting of p40, however, was found to be effective. More recently, selective IL-23 blockade has been extensively studied with promising preliminary results. To date, there are several ongoing randomized clinical trials investigating the safety and efficacy profiles of selective IL-23 inhibitors. Overall, the classes of anti-IL-12/IL-23 inhibitors and selective IL-23 inhibitors seem to be effective alternatives in patients who are nonresponders to anti-tumor necrosis factor-α agents, especially in a subgroup of secondary nonresponders. In addition, the immunogenicity and adverse event rates associated with antibodies against IL-12 and/or IL-23 seem to be very low. Considering all of this, these agents will be an important part of the treatment algorithm for patients with inflammatory bowel disease going forward.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://pubmed.ncbi.nlm.nih.gov/31360139
- OA Status
- green
- Cited By
- 51
- References
- 66
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W2996208796
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W2996208796Canonical identifier for this work in OpenAlex
- Title
-
The Expanding Role of Anti-IL-12 and/or Anti-IL-23 Antibodies in the Treatment of Inflammatory Bowel Disease.Work title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2019Year of publication
- Publication date
-
2019-05-01Full publication date if available
- Authors
-
Amir Kashani, David A. SchwartzList of authors in order
- Landing page
-
https://pubmed.ncbi.nlm.nih.gov/31360139Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
greenOpen access status per OpenAlex
- OA URL
-
https://www.ncbi.nlm.nih.gov/pmc/articles/6589846Direct OA link when available
- Concepts
-
Medicine, Inflammatory bowel disease, Immunology, Cytokine, Immunogenicity, Interleukin 23, Tumor necrosis factor alpha, Antibody, Pathogenesis, Disease, Inflammation, Interleukin, Adverse effect, Internal medicineTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
51Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 6, 2024: 7, 2023: 10, 2022: 12, 2021: 11Per-year citation counts (last 5 years)
- References (count)
-
66Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W2996208796 |
|---|---|
| doi | |
| ids.mag | 2996208796 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/31360139 |
| ids.openalex | https://openalex.org/W2996208796 |
| fwci | 4.97350704 |
| type | article |
| title | The Expanding Role of Anti-IL-12 and/or Anti-IL-23 Antibodies in the Treatment of Inflammatory Bowel Disease. |
| biblio.issue | 5 |
| biblio.volume | 15 |
| biblio.last_page | 265 |
| biblio.first_page | 255 |
| topics[0].id | https://openalex.org/T10134 |
| topics[0].field.id | https://openalex.org/fields/13 |
| topics[0].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[0].score | 0.9994999766349792 |
| topics[0].domain.id | https://openalex.org/domains/1 |
| topics[0].domain.display_name | Life Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/1311 |
| topics[0].subfield.display_name | Genetics |
| topics[0].display_name | Inflammatory Bowel Disease |
| topics[1].id | https://openalex.org/T10469 |
| topics[1].field.id | https://openalex.org/fields/24 |
| topics[1].field.display_name | Immunology and Microbiology |
| topics[1].score | 0.9993000030517578 |
| topics[1].domain.id | https://openalex.org/domains/1 |
| topics[1].domain.display_name | Life Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2403 |
| topics[1].subfield.display_name | Immunology |
| topics[1].display_name | Psoriasis: Treatment and Pathogenesis |
| topics[2].id | https://openalex.org/T13834 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9970999956130981 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2734 |
| topics[2].subfield.display_name | Pathology and Forensic Medicine |
| topics[2].display_name | Whipple's Disease and Interleukins |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C71924100 |
| concepts[0].level | 0 |
| concepts[0].score | 0.7263190746307373 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[0].display_name | Medicine |
| concepts[1].id | https://openalex.org/C2778260677 |
| concepts[1].level | 3 |
| concepts[1].score | 0.7140280604362488 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q917447 |
| concepts[1].display_name | Inflammatory bowel disease |
| concepts[2].id | https://openalex.org/C203014093 |
| concepts[2].level | 1 |
| concepts[2].score | 0.6288386583328247 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q101929 |
| concepts[2].display_name | Immunology |
| concepts[3].id | https://openalex.org/C2778690821 |
| concepts[3].level | 2 |
| concepts[3].score | 0.6103416681289673 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q212354 |
| concepts[3].display_name | Cytokine |
| concepts[4].id | https://openalex.org/C2780868878 |
| concepts[4].level | 3 |
| concepts[4].score | 0.5733058452606201 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q1660197 |
| concepts[4].display_name | Immunogenicity |
| concepts[5].id | https://openalex.org/C156730664 |
| concepts[5].level | 4 |
| concepts[5].score | 0.567013144493103 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q23308590 |
| concepts[5].display_name | Interleukin 23 |
| concepts[6].id | https://openalex.org/C17991360 |
| concepts[6].level | 2 |
| concepts[6].score | 0.5355700254440308 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q21173843 |
| concepts[6].display_name | Tumor necrosis factor alpha |
| concepts[7].id | https://openalex.org/C159654299 |
| concepts[7].level | 2 |
| concepts[7].score | 0.5283485054969788 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q79460 |
| concepts[7].display_name | Antibody |
| concepts[8].id | https://openalex.org/C2780942790 |
| concepts[8].level | 2 |
| concepts[8].score | 0.504050612449646 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q372016 |
| concepts[8].display_name | Pathogenesis |
| concepts[9].id | https://openalex.org/C2779134260 |
| concepts[9].level | 2 |
| concepts[9].score | 0.4847976267337799 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q12136 |
| concepts[9].display_name | Disease |
| concepts[10].id | https://openalex.org/C2776914184 |
| concepts[10].level | 2 |
| concepts[10].score | 0.4609672427177429 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q101991 |
| concepts[10].display_name | Inflammation |
| concepts[11].id | https://openalex.org/C74172505 |
| concepts[11].level | 3 |
| concepts[11].score | 0.45884832739830017 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q194908 |
| concepts[11].display_name | Interleukin |
| concepts[12].id | https://openalex.org/C197934379 |
| concepts[12].level | 2 |
| concepts[12].score | 0.41064319014549255 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q2047938 |
| concepts[12].display_name | Adverse effect |
| concepts[13].id | https://openalex.org/C126322002 |
| concepts[13].level | 1 |
| concepts[13].score | 0.233519047498703 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[13].display_name | Internal medicine |
| keywords[0].id | https://openalex.org/keywords/medicine |
| keywords[0].score | 0.7263190746307373 |
| keywords[0].display_name | Medicine |
| keywords[1].id | https://openalex.org/keywords/inflammatory-bowel-disease |
| keywords[1].score | 0.7140280604362488 |
| keywords[1].display_name | Inflammatory bowel disease |
| keywords[2].id | https://openalex.org/keywords/immunology |
| keywords[2].score | 0.6288386583328247 |
| keywords[2].display_name | Immunology |
| keywords[3].id | https://openalex.org/keywords/cytokine |
| keywords[3].score | 0.6103416681289673 |
| keywords[3].display_name | Cytokine |
| keywords[4].id | https://openalex.org/keywords/immunogenicity |
| keywords[4].score | 0.5733058452606201 |
| keywords[4].display_name | Immunogenicity |
| keywords[5].id | https://openalex.org/keywords/interleukin-23 |
| keywords[5].score | 0.567013144493103 |
| keywords[5].display_name | Interleukin 23 |
| keywords[6].id | https://openalex.org/keywords/tumor-necrosis-factor-alpha |
| keywords[6].score | 0.5355700254440308 |
| keywords[6].display_name | Tumor necrosis factor alpha |
| keywords[7].id | https://openalex.org/keywords/antibody |
| keywords[7].score | 0.5283485054969788 |
| keywords[7].display_name | Antibody |
| keywords[8].id | https://openalex.org/keywords/pathogenesis |
| keywords[8].score | 0.504050612449646 |
| keywords[8].display_name | Pathogenesis |
| keywords[9].id | https://openalex.org/keywords/disease |
| keywords[9].score | 0.4847976267337799 |
| keywords[9].display_name | Disease |
| keywords[10].id | https://openalex.org/keywords/inflammation |
| keywords[10].score | 0.4609672427177429 |
| keywords[10].display_name | Inflammation |
| keywords[11].id | https://openalex.org/keywords/interleukin |
| keywords[11].score | 0.45884832739830017 |
| keywords[11].display_name | Interleukin |
| keywords[12].id | https://openalex.org/keywords/adverse-effect |
| keywords[12].score | 0.41064319014549255 |
| keywords[12].display_name | Adverse effect |
| keywords[13].id | https://openalex.org/keywords/internal-medicine |
| keywords[13].score | 0.233519047498703 |
| keywords[13].display_name | Internal medicine |
| language | en |
| locations[0].id | pmid:31360139 |
| locations[0].is_oa | False |
| locations[0].source.id | https://openalex.org/S4306525036 |
| locations[0].source.issn | |
| locations[0].source.type | repository |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | |
| locations[0].source.is_core | False |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | PubMed |
| locations[0].source.host_organization | https://openalex.org/I1299303238 |
| locations[0].source.host_organization_name | National Institutes of Health |
| locations[0].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[0].license | |
| locations[0].pdf_url | |
| locations[0].version | publishedVersion |
| locations[0].raw_type | |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Gastroenterology & hepatology |
| locations[0].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/31360139 |
| locations[1].id | pmh:oai:pubmedcentral.nih.gov:6589846 |
| locations[1].is_oa | True |
| locations[1].source.id | https://openalex.org/S2764455111 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed Central |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | submittedVersion |
| locations[1].raw_type | Text |
| locations[1].license_id | |
| locations[1].is_accepted | False |
| locations[1].is_published | False |
| locations[1].raw_source_name | Gastroenterol Hepatol (N Y) |
| locations[1].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/6589846 |
| indexed_in | pubmed |
| authorships[0].author.id | https://openalex.org/A5090457083 |
| authorships[0].author.orcid | https://orcid.org/0000-0003-0779-6382 |
| authorships[0].author.display_name | Amir Kashani |
| authorships[0].affiliations[0].raw_affiliation_string | Dr Kashani is an instructor in medicine and Dr Schwartz is a professor of medicine in the Division of Gastroenterology, Hepatology, and Nutrition at the Vanderbilt Inflammatory Bowel Disease Clinic in Nashville, Tennessee. |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Amir Kashani |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Dr Kashani is an instructor in medicine and Dr Schwartz is a professor of medicine in the Division of Gastroenterology, Hepatology, and Nutrition at the Vanderbilt Inflammatory Bowel Disease Clinic in Nashville, Tennessee. |
| authorships[1].author.id | https://openalex.org/A5040276233 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-7486-8545 |
| authorships[1].author.display_name | David A. Schwartz |
| authorships[1].affiliations[0].raw_affiliation_string | Dr Kashani is an instructor in medicine and Dr Schwartz is a professor of medicine in the Division of Gastroenterology, Hepatology, and Nutrition at the Vanderbilt Inflammatory Bowel Disease Clinic in Nashville, Tennessee. |
| authorships[1].author_position | last |
| authorships[1].raw_author_name | David A Schwartz |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Dr Kashani is an instructor in medicine and Dr Schwartz is a professor of medicine in the Division of Gastroenterology, Hepatology, and Nutrition at the Vanderbilt Inflammatory Bowel Disease Clinic in Nashville, Tennessee. |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://www.ncbi.nlm.nih.gov/pmc/articles/6589846 |
| open_access.oa_status | green |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | The Expanding Role of Anti-IL-12 and/or Anti-IL-23 Antibodies in the Treatment of Inflammatory Bowel Disease. |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T04:12:42.849631 |
| primary_topic.id | https://openalex.org/T10134 |
| primary_topic.field.id | https://openalex.org/fields/13 |
| primary_topic.field.display_name | Biochemistry, Genetics and Molecular Biology |
| primary_topic.score | 0.9994999766349792 |
| primary_topic.domain.id | https://openalex.org/domains/1 |
| primary_topic.domain.display_name | Life Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/1311 |
| primary_topic.subfield.display_name | Genetics |
| primary_topic.display_name | Inflammatory Bowel Disease |
| related_works | https://openalex.org/W2045030084, https://openalex.org/W2391566606, https://openalex.org/W115674540, https://openalex.org/W29982137, https://openalex.org/W2008918018, https://openalex.org/W2006549602, https://openalex.org/W1969531010, https://openalex.org/W2001986928, https://openalex.org/W2186165848, https://openalex.org/W2080767539 |
| cited_by_count | 51 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 6 |
| counts_by_year[1].year | 2024 |
| counts_by_year[1].cited_by_count | 7 |
| counts_by_year[2].year | 2023 |
| counts_by_year[2].cited_by_count | 10 |
| counts_by_year[3].year | 2022 |
| counts_by_year[3].cited_by_count | 12 |
| counts_by_year[4].year | 2021 |
| counts_by_year[4].cited_by_count | 11 |
| counts_by_year[5].year | 2020 |
| counts_by_year[5].cited_by_count | 5 |
| locations_count | 2 |
| best_oa_location.id | pmh:oai:pubmedcentral.nih.gov:6589846 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S2764455111 |
| best_oa_location.source.issn | |
| best_oa_location.source.type | repository |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | |
| best_oa_location.source.is_core | False |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | PubMed Central |
| best_oa_location.source.host_organization | https://openalex.org/I1299303238 |
| best_oa_location.source.host_organization_name | National Institutes of Health |
| best_oa_location.source.host_organization_lineage | https://openalex.org/I1299303238 |
| best_oa_location.license | |
| best_oa_location.pdf_url | |
| best_oa_location.version | submittedVersion |
| best_oa_location.raw_type | Text |
| best_oa_location.license_id | |
| best_oa_location.is_accepted | False |
| best_oa_location.is_published | False |
| best_oa_location.raw_source_name | Gastroenterol Hepatol (N Y) |
| best_oa_location.landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/6589846 |
| primary_location.id | pmid:31360139 |
| primary_location.is_oa | False |
| primary_location.source.id | https://openalex.org/S4306525036 |
| primary_location.source.issn | |
| primary_location.source.type | repository |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | |
| primary_location.source.is_core | False |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | PubMed |
| primary_location.source.host_organization | https://openalex.org/I1299303238 |
| primary_location.source.host_organization_name | National Institutes of Health |
| primary_location.source.host_organization_lineage | https://openalex.org/I1299303238 |
| primary_location.license | |
| primary_location.pdf_url | |
| primary_location.version | publishedVersion |
| primary_location.raw_type | |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Gastroenterology & hepatology |
| primary_location.landing_page_url | https://pubmed.ncbi.nlm.nih.gov/31360139 |
| publication_date | 2019-05-01 |
| publication_year | 2019 |
| referenced_works | https://openalex.org/W2147277136, https://openalex.org/W2134836777, https://openalex.org/W2139298429, https://openalex.org/W2604523348, https://openalex.org/W2085127303, https://openalex.org/W2104439753, https://openalex.org/W2911723829, https://openalex.org/W2759528599, https://openalex.org/W2168521098, https://openalex.org/W1924457352, https://openalex.org/W2076889715, https://openalex.org/W2084119784, https://openalex.org/W1998599033, https://openalex.org/W1571088251, https://openalex.org/W2118434625, https://openalex.org/W1963921969, https://openalex.org/W1601925808, https://openalex.org/W2804431571, https://openalex.org/W2411836387, https://openalex.org/W2410520654, https://openalex.org/W1999283406, https://openalex.org/W2064645845, https://openalex.org/W2900611800, https://openalex.org/W2157961420, https://openalex.org/W2336474906, https://openalex.org/W2784524664, https://openalex.org/W2116828514, https://openalex.org/W1967937911, https://openalex.org/W4233817719, https://openalex.org/W2805537657, https://openalex.org/W1977817262, https://openalex.org/W2780850472, https://openalex.org/W2111913995, https://openalex.org/W2087905758, https://openalex.org/W1998895238, https://openalex.org/W1847326477, https://openalex.org/W1981714996, https://openalex.org/W2097935815, https://openalex.org/W2093531092, https://openalex.org/W2143625465, https://openalex.org/W2167264906, https://openalex.org/W2168987230, https://openalex.org/W2903540483, https://openalex.org/W2883220140, https://openalex.org/W1977158732, https://openalex.org/W2077531651, https://openalex.org/W2006249161, https://openalex.org/W2131727319, https://openalex.org/W2141679700, https://openalex.org/W2075090387, https://openalex.org/W2023733075, https://openalex.org/W1975588465, https://openalex.org/W2006741811, https://openalex.org/W2168654564, https://openalex.org/W2786974934, https://openalex.org/W2337677213, https://openalex.org/W2065307318, https://openalex.org/W2133782627, https://openalex.org/W1488772574, https://openalex.org/W1967774701, https://openalex.org/W2581525260, https://openalex.org/W2102156468, https://openalex.org/W2117966967, https://openalex.org/W2606398981, https://openalex.org/W2018075167, https://openalex.org/W2883739562 |
| referenced_works_count | 66 |
| abstract_inverted_index.a | 19, 168 |
| abstract_inverted_index.In | 173 |
| abstract_inverted_index.To | 122 |
| abstract_inverted_index.an | 72, 91, 201 |
| abstract_inverted_index.as | 18 |
| abstract_inverted_index.be | 90, 107, 153, 190, 200 |
| abstract_inverted_index.in | 22, 66, 77, 156, 167 |
| abstract_inverted_index.is | 4, 57 |
| abstract_inverted_index.of | 6, 11, 25, 32, 54, 75, 95, 101, 137, 144, 170, 195, 204 |
| abstract_inverted_index.to | 89, 106, 152, 161, 189 |
| abstract_inverted_index.The | 0 |
| abstract_inverted_index.all | 194 |
| abstract_inverted_index.and | 60, 97, 134, 147, 177 |
| abstract_inverted_index.are | 125, 159 |
| abstract_inverted_index.for | 208 |
| abstract_inverted_index.has | 114 |
| abstract_inverted_index.new | 38 |
| abstract_inverted_index.not | 87 |
| abstract_inverted_index.one | 5 |
| abstract_inverted_index.p40 | 65 |
| abstract_inverted_index.the | 23, 30, 63, 132, 142, 175, 205 |
| abstract_inverted_index.via | 52, 99 |
| abstract_inverted_index.was | 86, 104 |
| abstract_inverted_index.who | 158 |
| abstract_inverted_index.More | 109 |
| abstract_inverted_index.This | 56 |
| abstract_inverted_index.been | 115 |
| abstract_inverted_index.data | 41 |
| abstract_inverted_index.drew | 34 |
| abstract_inverted_index.have | 62, 70 |
| abstract_inverted_index.low. | 192 |
| abstract_inverted_index.many | 7 |
| abstract_inverted_index.p40, | 102 |
| abstract_inverted_index.part | 203 |
| abstract_inverted_index.seem | 151, 188 |
| abstract_inverted_index.that | 43 |
| abstract_inverted_index.this | 37 |
| abstract_inverted_index.very | 191 |
| abstract_inverted_index.will | 199 |
| abstract_inverted_index.with | 79, 118, 182, 210 |
| abstract_inverted_index.IL-12 | 17, 59, 84, 96, 185 |
| abstract_inverted_index.IL-23 | 33, 61, 98, 112, 139, 149, 187 |
| abstract_inverted_index.These | 68 |
| abstract_inverted_index.bowel | 27, 81, 212 |
| abstract_inverted_index.date, | 123 |
| abstract_inverted_index.event | 179 |
| abstract_inverted_index.found | 88, 105 |
| abstract_inverted_index.going | 214 |
| abstract_inverted_index.major | 20 |
| abstract_inverted_index.rates | 180 |
| abstract_inverted_index.their | 48 |
| abstract_inverted_index.there | 124 |
| abstract_inverted_index.these | 197 |
| abstract_inverted_index.this, | 196 |
| abstract_inverted_index.IL-23. | 55 |
| abstract_inverted_index.agents | 198 |
| abstract_inverted_index.and/or | 186 |
| abstract_inverted_index.become | 71 |
| abstract_inverted_index.effect | 50 |
| abstract_inverted_index.safety | 133 |
| abstract_inverted_index.target | 74 |
| abstract_inverted_index.toward | 36 |
| abstract_inverted_index.trials | 130 |
| abstract_inverted_index.Earlier | 14 |
| abstract_inverted_index.adverse | 178 |
| abstract_inverted_index.against | 45, 184 |
| abstract_inverted_index.agents, | 165 |
| abstract_inverted_index.because | 58 |
| abstract_inverted_index.classes | 143 |
| abstract_inverted_index.common. | 67 |
| abstract_inverted_index.disease | 213 |
| abstract_inverted_index.ongoing | 127 |
| abstract_inverted_index.pathway | 3 |
| abstract_inverted_index.several | 126 |
| abstract_inverted_index.studied | 117 |
| abstract_inverted_index.studies | 15 |
| abstract_inverted_index.subunit | 64 |
| abstract_inverted_index.However, | 29 |
| abstract_inverted_index.IL-12p40 | 46 |
| abstract_inverted_index.Overall, | 141 |
| abstract_inverted_index.blockade | 113 |
| abstract_inverted_index.clinical | 129 |
| abstract_inverted_index.cytokine | 21 |
| abstract_inverted_index.disease. | 28, 82 |
| abstract_inverted_index.efficacy | 135 |
| abstract_inverted_index.forward. | 215 |
| abstract_inverted_index.however, | 103 |
| abstract_inverted_index.necrosis | 163 |
| abstract_inverted_index.pathways | 10 |
| abstract_inverted_index.patients | 78, 157, 209 |
| abstract_inverted_index.profiles | 136 |
| abstract_inverted_index.proposed | 8 |
| abstract_inverted_index.rendered | 47 |
| abstract_inverted_index.results. | 121 |
| abstract_inverted_index.subgroup | 169 |
| abstract_inverted_index.Targeting | 83 |
| abstract_inverted_index.addition, | 174 |
| abstract_inverted_index.algorithm | 207 |
| abstract_inverted_index.attention | 35 |
| abstract_inverted_index.cytokine. | 39 |
| abstract_inverted_index.cytokines | 69 |
| abstract_inverted_index.discovery | 31 |
| abstract_inverted_index.effective | 154 |
| abstract_inverted_index.factor-α | 164 |
| abstract_inverted_index.important | 202 |
| abstract_inverted_index.indicated | 42 |
| abstract_inverted_index.primarily | 51 |
| abstract_inverted_index.promising | 119 |
| abstract_inverted_index.recently, | 110 |
| abstract_inverted_index.secondary | 171 |
| abstract_inverted_index.selective | 111, 138, 148 |
| abstract_inverted_index.targeting | 100 |
| abstract_inverted_index.treatment | 76, 206 |
| abstract_inverted_index.Coblockade | 94 |
| abstract_inverted_index.anti-tumor | 162 |
| abstract_inverted_index.antibodies | 44, 183 |
| abstract_inverted_index.associated | 181 |
| abstract_inverted_index.attractive | 73 |
| abstract_inverted_index.effective. | 108 |
| abstract_inverted_index.especially | 166 |
| abstract_inverted_index.inhibition | 53 |
| abstract_inverted_index.inhibitors | 146, 150 |
| abstract_inverted_index.intestinal | 12 |
| abstract_inverted_index.introduced | 16 |
| abstract_inverted_index.randomized | 128 |
| abstract_inverted_index.treatment. | 93 |
| abstract_inverted_index.Considering | 193 |
| abstract_inverted_index.efficacious | 92 |
| abstract_inverted_index.extensively | 116 |
| abstract_inverted_index.inhibitors. | 140 |
| abstract_inverted_index.interleukin | 1 |
| abstract_inverted_index.mechanistic | 9 |
| abstract_inverted_index.preliminary | 120 |
| abstract_inverted_index.selectively | 85 |
| abstract_inverted_index.Overwhelming | 40 |
| abstract_inverted_index.alternatives | 155 |
| abstract_inverted_index.inflammatory | 26, 80, 211 |
| abstract_inverted_index.pathogenesis | 24 |
| abstract_inverted_index.(IL)-12/IL-23 | 2 |
| abstract_inverted_index.inflammation. | 13 |
| abstract_inverted_index.investigating | 131 |
| abstract_inverted_index.nonresponders | 160 |
| abstract_inverted_index.immunogenicity | 176 |
| abstract_inverted_index.nonresponders. | 172 |
| abstract_inverted_index.anti-IL-12/IL-23 | 145 |
| abstract_inverted_index.anti-inflammatory | 49 |
| cited_by_percentile_year.max | 99 |
| cited_by_percentile_year.min | 97 |
| countries_distinct_count | 0 |
| institutions_distinct_count | 2 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.8399999737739563 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.95306816 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | True |